A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

Naomi Elster, Mattia Cremona, Clare Morgan, Sinéad Toomey, Aoife Carr, A O’Grady, Bryan T. Hennessy, Alex J. Eustace

Breast Cancer Research and Treatment · 2014 · 50 citations · 25 references

DOIFull text

Open access

Concepts

References

25